Published in N Engl J Med on March 28, 1996
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Infections in solid-organ transplant recipients. Clin Microbiol Rev (1997) 2.86
A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg (2001) 1.73
Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg (2005) 1.73
Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut (2002) 1.65
A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum (2012) 1.60
Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut (2003) 1.48
CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant. Liver Int (2012) 1.46
De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45
Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infection. Clin Gastroenterol Hepatol (2009) 1.41
Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog (2012) 1.35
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl (2012) 1.05
Hepatitis C and liver transplantation. Gut (1999) 1.03
Hepatitis C virus recurrence after liver transplantation. Gut (1999) 1.01
Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg (1999) 1.01
Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. AIDS (2009) 1.00
Clinical relevance of hepatitis C virus genotypes. Gut (1997) 0.95
Production and characterization of monoclonal antibodies specific for a conserved epitope within hepatitis C virus hypervariable region 1. J Virol (2001) 0.94
Molecular pathways differentiate hepatitis C virus (HCV) recurrence from acute cellular rejection in HCV liver recipients. Mol Med (2011) 0.91
Liver transplantation for alcoholic liver disease. World J Gastroenterol (2010) 0.91
Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. J Hepatol (2013) 0.90
Living-donor liver transplantation and hepatitis C. HPB Surg (2013) 0.90
Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut (2002) 0.89
Outcome of orthotopic liver transplantation in patients with haemophilia. Gut (1998) 0.89
Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence. Transplantation (2001) 0.89
Recurrence of hepatitis C after liver transplantation. Ann Gastroenterol (2013) 0.88
Predictors and outcome of early- versus late-onset major bacterial infections in liver transplant recipients receiving tacrolimus (FK506) as primary immunosuppression. Eur J Clin Microbiol Infect Dis (1997) 0.87
Impact of donor and recipient race on survival after hepatitis C-related liver transplantation. Transplantation (2012) 0.87
NK cells, innate immunity and hepatitis C infection after liver transplantation. Clin Infect Dis (2011) 0.86
Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. Liver Transpl Surg (1998) 0.86
Targeting HCV entry for development of therapeutics. Viruses (2010) 0.86
Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review. J Clin Transl Hepatol (2015) 0.86
Hepatitis C virus genotypes in liver transplant recipients: impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome. Transplantation (1997) 0.86
Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology. Gut (1999) 0.85
Role of liver transplantation in human immunodeficiency virus positive patients. World J Gastroenterol (2015) 0.85
Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy. Clinicoecon Outcomes Res (2014) 0.83
Irreversible liver failure: treatment by transplantation: part 3 of a series on liver cirrhosis. Dtsch Arztebl Int (2013) 0.83
New insights in recurrent HCV infection after liver transplantation. Clin Dev Immunol (2013) 0.83
Hepatitis GB virus-C/hepatitis G virus infection in liver disease. Arch Dis Child (1997) 0.83
Update on chronic viral hepatitis. Postgrad Med J (2001) 0.83
Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem. World J Gastroenterol (2014) 0.83
Strategies to reduce hepatitis C virus recurrence after liver transplantation. World J Hepatol (2013) 0.82
The natural killer cell response to HCV infection. Immune Netw (2013) 0.82
Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact. J Transl Med (2012) 0.82
Genetic diversity of hepatitis C virus predicts recurrent disease after liver transplantation. Virology (2010) 0.82
Racial differences in fibrosis progression after HCV-related liver transplantation. Transplantation (2012) 0.82
Liver transplantation for hepatitis C and alcoholic liver disease. J Transplant (2010) 0.81
Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future. World J Gastroenterol (2014) 0.81
Management practices of hepatitis C virus infected alcoholic hepatitis patients: A survey of physicians. World J Gastrointest Pharmacol Ther (2013) 0.81
Initial steroid-free immunosuppression after liver transplantation in recipients with hepatitis C virus related cirrhosis. World J Gastroenterol (2004) 0.81
Orthotopic liver transplantation and what to do during follow-up: recommendations for the practitioner. Nat Clin Pract Gastroenterol Hepatol (2008) 0.81
Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation. Liver Transpl (2016) 0.80
Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg (2006) 0.80
Angiostatin inhibits experimental liver fibrosis in mice. Int J Colorectal Dis (2004) 0.80
Treatment strategies for chronic hepatitis C prior to and following liver transplantation. World J Hepatol (2016) 0.80
Human liver transplantation as a model to study hepatitis C virus pathogenesis. Liver Transpl (2009) 0.79
Shear wave elastography in the evaluation of rejection or recurrent hepatitis after liver transplantation. Eur Radiol (2013) 0.79
Living donor liver transplantation to patients with hepatitis C virus cirrhosis. World J Gastroenterol (2006) 0.79
Liver transplantation and hepatitis C. Int J Hepatol (2012) 0.79
Hepatitis C virus recurrence in living donor liver transplant recipients. Dig Dis Sci (2004) 0.79
Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis. BMJ Open Gastroenterol (2016) 0.78
Surgical vs percutaneous radiofrequency ablation for hepatocellular carcinoma in dangerous locations. World J Gastroenterol (2011) 0.78
Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon. Dig Dis Sci (2009) 0.78
Liver transplantation for chronic liver disease: advances and controversies in an era of organ shortages. Postgrad Med J (2002) 0.78
An extended treatment protocol with pegylated interferon and ribavirin for hepatitis C recurrence after liver transplantation. World J Hepatol (2011) 0.78
Liver transplantation in patients with chronic hepatitis C and alcoholism. Dig Dis Sci (1999) 0.78
Virus-drug interactions--molecular insight into immunosuppression and HCV. Nat Rev Gastroenterol Hepatol (2012) 0.77
Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation. World J Gastroenterol (2013) 0.77
A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection. J Clin Exp Hepatol (2012) 0.77
Cyclosporin A, but not tacrolimus, negatively affects the hepatic extraction fraction of hepatobiliary scintigraphy in liver transplant recipients. EJNMMI Res (2014) 0.77
Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation. World J Gastroenterol (2015) 0.77
Liver transplantation in adults: Choosing the appropriate timing. World J Gastrointest Pharmacol Ther (2012) 0.77
Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin. Dig Dis Sci (2011) 0.77
Management of HCV infection and liver transplantation. Int J Med Sci (2006) 0.77
Anti-hepatitis C virus core IgM antibodies correlate with hepatitis C recurrence and its severity in liver transplant patients. Gut (2000) 0.77
Histopathological evaluation of recurrent hepatitis C after liver transplantation: a review. World J Gastroenterol (2014) 0.77
Recurrence of hepatitis C virus genotype-4 infection following orthotopic liver transplantation: natural history and predictors of outcome. Ann Saudi Med (2009) 0.77
Management of viral hepatitis in liver transplant recipients. Clin Mol Hepatol (2014) 0.77
HCV in liver transplantation. Semin Immunopathol (2012) 0.76
Hepatitis C and liver transplantation. Hippokratia (2009) 0.76
IL-2 Receptor Antagonist (Basiliximab) Is Associated with Rapid Fibrosis Progression in Patients with Recurrent Hepatitis C after Liver Transplantation Using Serial Biopsy Specimens. Int J Organ Transplant Med (2010) 0.76
Antiviral treatment for hepatitis C virus infection after liver transplantation. Hepat Res Treat (2010) 0.76
Immunological dysfunction during or after antiviral therapy for recurrent hepatitis C reduces graft survival. Hepatol Int (2013) 0.76
Treatment options for HCV nonresponders and relapse patients. Gastroenterol Hepatol (N Y) (2010) 0.76
Outcome of orthotopic liver transplantation in patients with hepatitis C. Dig Dis Sci (2002) 0.75
Inhibition of tumour necrosis factor-alpha in patients with chronic hepatitis C infection. Clin Rheumatol (2006) 0.75
Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 0.75
A B C d e f g ... Can J Infect Dis (1996) 0.75
Clinical management of patients with recurrent viral hepatitis after liver transplantation. J Ultrasound (2007) 0.75
Recurrent hepatitis C after living donor liver transplantation detected by Tc-99m GSA liver scintigraphy. Dig Dis Sci (2006) 0.75
Diagnostic value of anti-hepatitis C virus (HCV) core immunoglobulin M in recurrence of HCV infection after orthotopic liver transplantation. J Clin Microbiol (1999) 0.75
Long term outcome of liver transplantation for viral hepatitis: is there a need to re-evaluate patient selection? Gut (1999) 0.75
Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop. Can J Gastroenterol (2006) 0.75
Antihepatitis C virus therapy in liver transplanted patients. Ther Clin Risk Manag (2006) 0.75
Update in liver transplantation. Can Fam Physician (1999) 0.75
Enhancement of Programmed Death Ligand 2 on Hepatitis C Virus Infected Hepatocytes by Calcineurin Inhibitors. Transplantation (2015) 0.75
Recurrence of hepatitis C after liver transplantation is associated with increased systemic IL-10 levels. Mediators Inflamm (2001) 0.75
Hepatitis C infection after blood product transfusion. Arch Dis Child (1996) 0.75
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Early indicators of prognosis in fulminant hepatic failure. Gastroenterology (1989) 7.43
Cost analysis of early discharge after hip fracture. BMJ (1993) 6.64
Deaths from low dose paracetamol poisoning. BMJ (1998) 6.63
Anti-tuberculous therapy and acute liver failure. Lancet (1995) 6.27
Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med (2000) 6.07
Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (2001) 6.05
Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol (1993) 5.26
Acute liver failure: redefining the syndromes. Lancet (1993) 4.99
Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med (2000) 4.98
Vulnerability genes or plasticity genes? Mol Psychiatry (2009) 4.96
Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet (1990) 4.57
Urinary D-glucaric-acid excretion as a test for hepatic enzyme induction in man. Lancet (1971) 4.49
Liver transplantation in man. I. Observations on technique and organization in five cases. Br Med J (1968) 4.38
Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet (1990) 4.27
Daily variation of particulate air pollution and poor cardiac autonomic control in the elderly. Environ Health Perspect (1999) 4.07
Cell-mediated immunity to a human liver-specific antigen in patients with active chronic hepatitis and primary biliary cirrhosis. Lancet (1972) 3.90
The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 3.78
Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol (1998) 3.77
Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis. Lancet (1974) 3.61
Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess (2007) 3.40
Structured patient education: the diabetes X-PERT Programme makes a difference. Diabet Med (2006) 3.36
Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med (1978) 3.28
Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med (1992) 3.24
Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol (1996) 3.22
NHLBI Family Heart Study: objectives and design. Am J Epidemiol (1996) 3.21
Lymphocyte cytotoxicity to isolated hepatocytes in chronic active hepatitis. Nature (1974) 3.17
Purification and characterization of human liver-specific membrane lipoprotein (LSP). Clin Exp Immunol (1977) 3.13
Improved survival after orthotopic liver grafting. Br Med J (Clin Res Ed) (1981) 3.09
Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol (1982) 3.09
Mutations that alter the ability of the Escherichia coli cyclic AMP receptor protein to activate transcription. Nucleic Acids Res (1990) 3.08
Presence of a newly described human DNA virus (TTV) in patients with liver disease. Lancet (1998) 3.06
Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg (1988) 3.04
Typhoid Carriers -A Study of Their Disease Producing Potentialities Over a Series of Years as Indicated by a Study of Cases. Am J Public Health Nations Health (1936) 3.00
Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet (1973) 2.98
Use of partial cardiopulmonary bypass during the anhepatic phase of orthotopic liver grafting. Lancet (1979) 2.98
Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ (1991) 2.94
The canals of Hering and hepatic stem cells in humans. Hepatology (1999) 2.93
More donor organs for transplantation. Elective ventilation proposals. J R Coll Physicians Lond (1993) 2.91
Multisystem involvement in chronic liver disease. Studies on the incidence and pathogenesis. Am J Med (1973) 2.88
Altered calcium metabolism in epileptic children on anticonvulsants. Br Med J (1971) 2.86
The arthropathy of idiopathic haemochromatosis. Q J Med (1968) 2.85
Hepatitis B virus infection in medical and health care personnel. Br Med J (Clin Res Ed) (1982) 2.85
Liver transplantation after paracetamol overdose. BMJ (1991) 2.81
New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol (1997) 2.78
Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet (1989) 2.76
Liver in Felty's syndrome. Br Med J (1970) 2.75
Hepatic damage and death from overdose of paracetamol. Lancet (1973) 2.70
Extrahepatic biliary atresia versus neonatal hepatitis. Review of 137 prospectively investigated infants. Arch Dis Child (1976) 2.67
Cyclosporin A in cadaveric organ transplantation. Br Med J (Clin Res Ed) (1981) 2.67
Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med (1991) 2.65
Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology (1999) 2.62
Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology (1988) 2.60
Treatment of hepatic encephalopathy. N Engl J Med (1997) 2.60
Liver transplantation. Curr Probl Surg (1979) 2.57
Hepatic angiomyolipoma: a clinicopathologic study of 30 cases and delineation of unusual morphologic variants. Am J Surg Pathol (1999) 2.53
Treatment of fulminant hepatic failure by polyacrylonitrile-membrane haemodialysis. Lancet (1977) 2.53
Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases. Gut (1998) 2.51
Orthotopic liver transplantation: the first 60 patients. Br Med J (1977) 2.50
A habitable fluvio-lacustrine environment at Yellowknife Bay, Gale crater, Mars. Science (2013) 2.50
The systemic inflammatory response syndrome in acute liver failure. Hepatology (2000) 2.47
Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology (2000) 2.45
The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J Clin Endocrinol Metab (2004) 2.44
Attentional bias in anxiety and depression: the role of awareness. Br J Clin Psychol (1995) 2.43
Developing and deploying a patient safety program in a large health care delivery system: you can't fix what you don't know about. Jt Comm J Qual Improv (2001) 2.42
Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med (1995) 2.41
Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med (1980) 2.41
1 -Antitrypsin deficiency and neonatal hepatitis. Br Med J (1972) 2.40
General practice orthopaedic outpatient referrals in North Staffordshire. Br Med J (Clin Res Ed) (1983) 2.38
Relation of renal impairment and haemorrhagic diathesis to endotoxaemia in fulminant hepatic failure. Lancet (1974) 2.37
Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations. Adv Exp Med Biol (1997) 2.35
Salmonellosis as a Public Health Problem in Wartime. Am J Public Health Nations Health (1944) 2.34
Genotypic analysis of hepatitis C virus in American patients. Hepatology (1994) 2.33
Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology (1993) 2.32
Long-term anticonvulsant therapy worsens outcome in paracetamol-induced fulminant hepatic failure. Hum Exp Toxicol (1992) 2.31
Influence of delta infection on severity of hepatitis B. Lancet (1982) 2.31
Increased long-term survival in variceal haemorrhage using injection sclerotherapy. Results of a controlled trial. Lancet (1982) 2.30
Treatment of secondary hepatic tumours by ligation of hepatic artery and infusion of cytotoxic drugs. Lancet (1970) 2.25
Cytomegalovirus hepatitis in the adult. Lancet (1967) 2.20
Serial prothrombin time as prognostic indicator in paracetamol induced fulminant hepatic failure. BMJ (1990) 2.18
Detection of hepatitis-B antigen by radioimmunoassay in chronic liver disease and hepatocellular carcinoma in Great Britain. Lancet (1973) 2.17
Assessment of non-mydriatic fundus photography in detection of diabetic retinopathy. Br Med J (Clin Res Ed) (1986) 2.16
Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care (1999) 2.16
Portal hypertension in idiopathic tropical splenomegaly. Lancet (1966) 2.16
Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet (1968) 2.14
Measurement and characterization of postischemic free radical generation in the isolated perfused heart. J Biol Chem (1989) 2.14
Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999. Thorax (2002) 2.12
A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993). Gastroenterology (1995) 2.11
H2-receptor antagonists and antacids in the prevention of acute gastrointestinal haemorrhage in fulminant hepatic failure. Two controlled trials. Lancet (1977) 2.10
Reduction of absorption of paracetamol by activated charcoal and cholestyramine: a possible therapeutic measure. Br Med J (1973) 2.09
A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily. J Immunol (1992) 2.09
Arthropathy of haemochromatosis. Clinical and radiological analysis of 63 patients with iron overload. Ann Rheum Dis (1970) 2.09
Detection, treatment, and follow up of women with Chlamydia trachomatis infection seeking abortion in inner city general practices. BMJ (1989) 2.08
Simple hypothermic preservation for transporting human livers long distances for transplantation. Report of 12 cases. Transplantation (1977) 2.08
Early and intensive therapy of intravascular coagulation in acute liver failure. Lancet (1971) 2.08
Cell-mediated immune responses in chronic liver diseases. Br Med J (1972) 2.05